Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Mimedx (MDXG) Revenue (2016 - 2026)

Mimedx's Revenue history spans 16 years, with the latest figure at $59.0 million for Q1 2026.

  • On a quarterly basis, Revenue fell 33.12% to $59.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $389.4 million, a 10.51% increase, with the full-year FY2025 number at $418.6 million, up 19.99% from a year prior.
  • Revenue hit $59.0 million in Q1 2026 for Mimedx, down from $118.1 million in the prior quarter.
  • Over the last five years, Revenue for MDXG hit a ceiling of $118.1 million in Q4 2025 and a floor of $58.9 million in Q1 2022.
  • Historically, Revenue has averaged $83.3 million across 5 years, with a median of $84.1 million in 2024.
  • Biggest five-year swings in Revenue: surged 46.37% in 2022 and later plummeted 33.12% in 2026.
  • Tracing MDXG's Revenue over 5 years: stood at $74.4 million in 2022, then grew by 16.75% to $86.8 million in 2023, then increased by 7.0% to $92.9 million in 2024, then rose by 27.11% to $118.1 million in 2025, then plummeted by 50.05% to $59.0 million in 2026.
  • Business Quant data shows Revenue for MDXG at $59.0 million in Q1 2026, $118.1 million in Q4 2025, and $113.7 million in Q3 2025.